Advertisement

Gilead buying Corus Pharma for $365M

FOSTER CITY, Calif., July 20 (UPI) -- Gilead Sciences Inc., which is based in Foster City, Calif., will pay $365 million for Corus Pharma.

The deal for the privately held Seattle company, which makes specialty products for respiratory and infectious diseases, is set to close by the end of the month, Gilead said Wednesday.

Advertisement

Also, Gilead has reached an agreement with Novartis Vaccine and Diagnostics Inc., whereby Novartis will end its litigation against Corus for an undisclosed payment.

Latest Headlines

Advertisement

Trending Stories

Advertisement

Follow Us

Advertisement